← 產業報告目錄
Retinal Degenerative Disease Treatment Industry Research Report 2026
出版商 APO Research產業別 Software & IT Services出版日期 2026-07-04頁數 138報告編號 APO-f8f712944d
授權報價
| Single User | $2,950 USD |
| Multi User | $4,430 USD |
| Enterprise | $5,900 USD |
報告摘要
The global Retinal Degenerative Disease Treatment market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Retinal Degenerative Disease Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Retinal Degenerative Disease Treatment market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Retinal Degenerative Disease Treatment market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Retinal Degenerative Disease Treatment include Sucampo Pharmaceuticals, Vivani Medical(Second Sight Medical), Roche, ReNeuron, ReGenX Biosciences, Regeneron Pharmaceuticals, Orphagen Pharmaceuticals, Inc., Okuvision and Ocugen, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Retinal Degenerative Disease Treatment market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Retinal Degenerative Disease Treatment.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Retinal Degenerative Disease Treatment Market by Company
Sucampo Pharmaceuticals
Vivani Medical(Second Sight Medical)
Roche
ReNeuron
ReGenX Biosciences
Regeneron Pharmaceuticals
Orphagen Pharmaceuticals, Inc.
Okuvision
Ocugen
Novartis
Nano Retina
M's Science Corporation
Mimetogen Pharmaceuticals Inc.
Kanghong Pharma
Ionis Pharmaceuticals, Inc.
International Stem Cell Corporation
InFlectis BioScience
Grupo Ferrer Internacional, S.A.
GenSight Biologics S.A.
Genethon
Genable Technologies Limited
Dompe Farmaceutici S.p.A.
Caladrius Biosciences, Inc.
Bayer HealthCare
Astellas Pharma Inc.
Amarantus BioScience
Retinal Degenerative Disease Treatment Segment by Type
Age Related Macular Degeneration (AMD) Treatment
Retinitis Pigmentosa (RP) Treatment
Retinal Degenerative Disease Treatment Segment by Application
20 to 60 Years Old
60 and Over
Others
Retinal Degenerative Disease Treatment Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Retinal Degenerative Disease Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Retinal Degenerative Disease Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Retinal Degenerative Disease Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Retinal Degenerative Disease Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
目錄 Table of Contents
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Retinal Degenerative Disease Treatment by Type
2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
2.2.2 Age Related Macular Degeneration (AMD) Treatment
2.2.3 Retinitis Pigmentosa (RP) Treatment
2.3 Retinal Degenerative Disease Treatment by Application
2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
2.3.2 20 to 60 Years Old
2.3.3 60 and Over
2.3.4 Others
2.4 Assumptions and Limitations
3 Retinal Degenerative Disease Treatment Breakdown Data by Type
3.1 Global Retinal Degenerative Disease Treatment Historic Market Size by Type (2021-2026)
3.2 Global Retinal Degenerative Disease Treatment Forecasted Market Size by Type (2027-2032)
4 Retinal Degenerative Disease Treatment Breakdown Data by Application
4.1 Global Retinal Degenerative Disease Treatment Historic Market Size by Application (2021-2026)
4.2 Global Retinal Degenerative Disease Treatment Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
5.1 Global Retinal Degenerative Disease Treatment Market Perspective (2021-2032)
5.2 Global Retinal Degenerative Disease Treatment Growth Trends by Region
5.2.1 Global Retinal Degenerative Disease Treatment Market Size by Region: 2021 VS 2025 VS 2032
5.2.2 Retinal Degenerative Disease Treatment Historic Market Size by Region (2021-2026)
5.2.3 Retinal Degenerative Disease Treatment Forecasted Market Size by Region (2027-2032)
5.3 Retinal Degenerative Disease Treatment Market Dynamics
5.3.1 Retinal Degenerative Disease Treatment Industry Trends
5.3.2 Retinal Degenerative Disease Treatment Market Drivers
5.3.3 Retinal Degenerative Disease Treatment Market Challenges
5.3.4 Retinal Degenerative Disease Treatment Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Retinal Degenerative Disease Treatment Players by Revenue
6.1.1 Global Top Retinal Degenerative Disease Treatment Players by Revenue (2021-2026)
6.1.2 Global Retinal Degenerative Disease Treatment Revenue Market Share by Players (2021-2026)
6.2 Global Retinal Degenerative Disease Treatment Industry Players Ranking, 2023 VS 2024 VS 2025
6.3 Global Key Players of Retinal Degenerative Disease Treatment Head Office and Area Served
6.4 Global Retinal Degenerative Disease Treatment Players, Product Type & Application
6.5 Global Retinal Degenerative Disease Treatment Manufacturers Established Date
6.6 Global Retinal Degenerative Disease Treatment Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Retinal Degenerative Disease Treatment Market Size (2021-2032)
7.2 North America Retinal Degenerative Disease Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
7.3 North America Retinal Degenerative Disease Treatment Market Size by Country (2021-2026)
7.4 North America Retinal Degenerative Disease Treatment Market Size by Country (2027-2032)
7.5 United States
7.5 United States
7.6 Canada
7.7 Mexico
8 Europe
8.1 Europe Retinal Degenerative Disease Treatment Market Size (2021-2032)
8.2 Europe Retinal Degenerative Disease Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
8.3 Europe Retinal Degenerative Disease Treatment Market Size by Country (2021-2026)
8.4 Europe Retinal Degenerative Disease Treatment Market Size by Country (2027-2032)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Spain
8.10 Russia
8.11 Netherlands
8.12 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Retinal Degenerative Disease Treatment Market Size (2021-2032)
9.2 Asia-Pacific Retinal Degenerative Disease Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
9.3 Asia-Pacific Retinal Degenerative Disease Treatment Market Size by Country (2021-2026)
9.4 Asia-Pacific Retinal Degenerative Disease Treatment Market Size by Country (2027-2032)
9.5 China
9.6 Japan
9.7 South Korea
9.8 India
9.9 Australia
9.10 China Taiwan
9.11 Southeast Asia
10 South America
10.1 South America Retinal Degenerative Disease Treatment Market Size (2021-2032)
10.2 South America Retinal Degenerative Disease Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
10.3 South America Retinal Degenerative Disease Treatment Market Size by Country (2021-2026)
10.4 South America Retinal Degenerative Disease Treatment Market Size by Country (2027-2032)
10.5 Brazil
10.6 Argentina
10.7 Chile
10.8 Colombia
10.9 Peru
11 Middle East & Africa
11.1 Middle East & Africa Retinal Degenerative Disease Treatment Market Size (2021-2032)
11.2 Middle East & Africa Retinal Degenerative Disease Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
11.3 Middle East & Africa Retinal Degenerative Disease Treatment Market Size by Country (2021-2026)
11.4 Middle East & Africa Retinal Degenerative Disease Treatment Market Size by Country (2027-2032)
11.5 Saudi Arabia
11.6 Israel
11.7 United Arab Emirates
11.8 Turkey
11.9 Iran
11.10 Egypt
12 Players Profiled
12.1 Sucampo Pharmaceuticals
12.1.1 Sucampo Pharmaceuticals Company Information
12.1.2 Sucampo Pharmaceuticals Business Overview
12.1.3 Sucampo Pharmaceuticals Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
12.1.4 Sucampo Pharmaceuticals Retinal Degenerative Disease Treatment Product Portfolio
12.1.5 Sucampo Pharmaceuticals Recent Developments
12.2 Vivani Medical(Second Sight Medical)
12.2.1 Vivani Medical(Second Sight Medical) Company Information
12.2.2 Vivani Medical(Second Sight Medical) Business Overview
12.2.3 Vivani Medical(Second Sight Medical) Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
12.2.4 Vivani Medical(Second Sight Medical) Retinal Degenerative Disease Treatment Product Portfolio
12.2.5 Vivani Medical(Second Sight Medical) Recent Developments
12.3 Roche
12.3.1 Roche Company Information
12.3.2 Roche Business Overview
12.3.3 Roche Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
12.3.4 Roche Retinal Degenerative Disease Treatment Product Portfolio
12.3.5 Roche Recent Developments
12.4 ReNeuron
12.4.1 ReNeuron Company Information
12.4.2 ReNeuron Business Overview
12.4.3 ReNeuron Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
12.4.4 ReNeuron Retinal Degenerative Disease Treatment Product Portfolio
12.4.5 ReNeuron Recent Developments
12.5 ReGenX Biosciences
12.5.1 ReGenX Biosciences Company Information
12.5.2 ReGenX Biosciences Business Overview
12.5.3 ReGenX Biosciences Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
12.5.4 ReGenX Biosciences Retinal Degenerative Disease Treatment Product Portfolio
12.5.5 ReGenX Biosciences Recent Developments
12.6 Regeneron Pharmaceuticals
12.6.1 Regeneron Pharmaceuticals Company Information
12.6.2 Regeneron Pharmaceuticals Business Overview
12.6.3 Regeneron Pharmaceuticals Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
12.6.4 Regeneron Pharmaceuticals Retinal Degenerative Disease Treatment Product Portfolio
12.6.5 Regeneron Pharmaceuticals Recent Developments
12.7 Orphagen Pharmaceuticals, Inc.
12.7.1 Orphagen Pharmaceuticals, Inc. Company Information
12.7.2 Orphagen Pharmaceuticals, Inc. Business Overview
12.7.3 Orphagen Pharmaceuticals, Inc. Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
12.7.4 Orphagen Pharmaceuticals, Inc. Retinal Degenerative Disease Treatment Product Portfolio
12.7.5 Orphagen Pharmaceuticals, Inc. Recent Developments
12.8 Okuvision
12.8.1 Okuvision Company Information
12.8.2 Okuvision Business Overview
12.8.3 Okuvision Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
12.8.4 Okuvision Retinal Degenerative Disease Treatment Product Portfolio
12.8.5 Okuvision Recent Developments
12.9 Ocugen
12.9.1 Ocugen Company Information
12.9.2 Ocugen Business Overview
12.9.3 Ocugen Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
12.9.4 Ocugen Retinal Degenerative Disease Treatment Product Portfolio
12.9.5 Ocugen Recent Developments
12.10 Novartis
12.10.1 Novartis Company Information
12.10.2 Novartis Business Overview
12.10.3 Novartis Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
12.10.4 Novartis Retinal Degenerative Disease Treatment Product Portfolio
12.10.5 Novartis Recent Developments
12.11 Nano Retina
12.11.1 Nano Retina Company Information
12.11.2 Nano Retina Business Overview
12.11.3 Nano Retina Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
12.11.4 Nano Retina Retinal Degenerative Disease Treatment Product Portfolio
12.11.5 Nano Retina Recent Developments
12.12 M's Science Corporation
12.12.1 M's Science Corporation Company Information
12.12.2 M's Science Corporation Business Overview
12.12.3 M's Science Corporation Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
12.12.4 M's Science Corporation Retinal Degenerative Disease Treatment Product Portfolio
12.12.5 M's Science Corporation Recent Developments
12.13 Mimetogen Pharmaceuticals Inc.
12.13.1 Mimetogen Pharmaceuticals Inc. Company Information
12.13.2 Mimetogen Pharmaceuticals Inc. Business Overview
12.13.3 Mimetogen Pharmaceuticals Inc. Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
12.13.4 Mimetogen Pharmaceuticals Inc. Retinal Degenerative Disease Treatment Product Portfolio
12.13.5 Mimetogen Pharmaceuticals Inc. Recent Developments
12.14 Kanghong Pharma
12.14.1 Kanghong Pharma Company Information
12.14.2 Kanghong Pharma Business Overview
12.14.3 Kanghong Pharma Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
12.14.4 Kanghong Pharma Retinal Degenerative Disease Treatment Product Portfolio
12.14.5 Kanghong Pharma Recent Developments
12.15 Ionis Pharmaceuticals, Inc.
12.15.1 Ionis Pharmaceuticals, Inc. Company Information
12.15.2 Ionis Pharmaceuticals, Inc. Business Overview
12.15.3 Ionis Pharmaceuticals, Inc. Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
12.15.4 Ionis Pharmaceuticals, Inc. Retinal Degenerative Disease Treatment Product Portfolio
12.15.5 Ionis Pharmaceuticals, Inc. Recent Developments
12.16 International Stem Cell Corporation
12.16.1 International Stem Cell Corporation Company Information
12.16.2 International Stem Cell Corporation Business Overview
12.16.3 International Stem Cell Corporation Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
12.16.4 International Stem Cell Corporation Retinal Degenerative Disease Treatment Product Portfolio
12.16.5 International Stem Cell Corporation Recent Developments
12.17 InFlectis BioScience
12.17.1 InFlectis BioScience Company Information
12.17.2 InFlectis BioScience Business Overview
12.17.3 InFlectis BioScience Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
12.17.4 InFlectis BioScience Retinal Degenerative Disease Treatment Product Portfolio
12.17.5 InFlectis BioScience Recent Developments
12.18 Grupo Ferrer Internacional, S.A.
12.18.1 Grupo Ferrer Internacional, S.A. Company Information
12.18.2 Grupo Ferrer Internacional, S.A. Business Overview
12.18.3 Grupo Ferrer Internacional, S.A. Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
12.18.4 Grupo Ferrer Internacional, S.A. Retinal Degenerative Disease Treatment Product Portfolio
12.18.5 Grupo Ferrer Internacional, S.A. Recent Developments
12.19 GenSight Biologics S.A.
12.19.1 GenSight Biologics S.A. Company Information
12.19.2 GenSight Biologics S.A. Business Overview
12.19.3 GenSight Biologics S.A. Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
12.19.4 GenSight Biologics S.A. Retinal Degenerative Disease Treatment Product Portfolio
12.19.5 GenSight Biologics S.A. Recent Developments
12.20 Genethon
12.20.1 Genethon Company Information
12.20.2 Genethon Business Overview
12.20.3 Genethon Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
12.20.4 Genethon Retinal Degenerative Disease Treatment Product Portfolio
12.20.5 Genethon Recent Developments
12.21 Genable Technologies Limited
12.21.1 Genable Technologies Limited Company Information
12.21.2 Genable Technologies Limited Business Overview
12.21.3 Genable Technologies Limited Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
12.21.4 Genable Technologies Limited Retinal Degenerative Disease Treatment Product Portfolio
12.21.5 Genable Technologies Limited Recent Developments
12.22 Dompe Farmaceutici S.p.A.
12.22.1 Dompe Farmaceutici S.p.A. Company Information
12.22.2 Dompe Farmaceutici S.p.A. Business Overview
12.22.3 Dompe Farmaceutici S.p.A. Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
12.22.4 Dompe Farmaceutici S.p.A. Retinal Degenerative Disease Treatment Product Portfolio
12.22.5 Dompe Farmaceutici S.p.A. Recent Developments
12.23 Caladrius Biosciences, Inc.
12.23.1 Caladrius Biosciences, Inc. Company Information
12.23.2 Caladrius Biosciences, Inc. Business Overview
12.23.3 Caladrius Biosciences, Inc. Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
12.23.4 Caladrius Biosciences, Inc. Retinal Degenerative Disease Treatment Product Portfolio
12.23.5 Caladrius Biosciences, Inc. Recent Developments
12.24 Bayer HealthCare
12.24.1 Bayer HealthCare Company Information
12.24.2 Bayer HealthCare Business Overview
12.24.3 Bayer HealthCare Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
12.24.4 Bayer HealthCare Retinal Degenerative Disease Treatment Product Portfolio
12.24.5 Bayer HealthCare Recent Developments
12.25 Astellas Pharma Inc.
12.25.1 Astellas Pharma Inc. Company Information
12.25.2 Astellas Pharma Inc. Business Overview
12.25.3 Astellas Pharma Inc. Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
12.25.4 Astellas Pharma Inc. Retinal Degenerative Disease Treatment Product Portfolio
12.25.5 Astellas Pharma Inc. Recent Developments
12.26 Amarantus BioScience
12.26.1 Amarantus BioScience Company Information
12.26.2 Amarantus BioScience Business Overview
12.26.3 Amarantus BioScience Revenue in Retinal Degenerative Disease Treatment Business (2021-2026)
12.26.4 Amarantus BioScience Retinal Degenerative Disease Treatment Product Portfolio
12.26.5 Amarantus BioScience Recent Developments
13 Report Conclusion
14 Disclaimer
圖表清單 List of Tables & Figures
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
Table 5. Global Retinal Degenerative Disease Treatment Market Size by Type (2021-2026) & (US$ Million)
Table 6. Global Retinal Degenerative Disease Treatment Revenue Market Share by Type (2021-2026)
Table 7. Global Retinal Degenerative Disease Treatment Forecasted Market Size by Type (2027-2032) & (US$ Million)
Table 8. Global Retinal Degenerative Disease Treatment Revenue Market Share by Type (2027-2032)
Table 9. Global Retinal Degenerative Disease Treatment Market Size by Application (2021-2026) & (US$ Million)
Table 10. Global Retinal Degenerative Disease Treatment Revenue Market Share by Application (2021-2026)
Table 11. Global Retinal Degenerative Disease Treatment Forecasted Market Size by Application (2027-2032) & (US$ Million)
Table 12. Global Retinal Degenerative Disease Treatment Revenue Market Share by Application (2027-2032)
Table 13. Global Retinal Degenerative Disease Treatment Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Table 14. Global Retinal Degenerative Disease Treatment Market Size by Region (2021-2026) & (US$ Million)
Table 15. Global Retinal Degenerative Disease Treatment Market Share by Region (2021-2026)
Table 16. Global Retinal Degenerative Disease Treatment Forecasted Market Size by Region (2027-2032) & (US$ Million)
Table 17. Global Retinal Degenerative Disease Treatment Market Share by Region (2027-2032)
Table 18. Retinal Degenerative Disease Treatment Industry Trends
Table 19. Retinal Degenerative Disease Treatment Industry Drivers
Table 20. Retinal Degenerative Disease Treatment Industry Opportunities and Challenges
Table 21. Retinal Degenerative Disease Treatment Market Restraints
Table 22. Global Top Retinal Degenerative Disease Treatment Players by Revenue (US$ Million) & (2021-2026)
Table 23. Global Retinal Degenerative Disease Treatment Revenue Market Share by Players (2021-2026)
Table 24. Global Retinal Degenerative Disease Treatment Industry Players Ranking, 2024 VS 2025 VS 2026
Table 25. Global Key Players of Retinal Degenerative Disease Treatment, Headquarters and Area Served
Table 26. Global Retinal Degenerative Disease Treatment Players, Product Type & Application
Table 27. Global Players Market Concentration Ratio (CR5 and HHI)
Table 28. Global Retinal Degenerative Disease Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
Table 29. Players Mergers & Acquisitions, Expansion Plans
Table 30. North America Retinal Degenerative Disease Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 31. North America Retinal Degenerative Disease Treatment Market Size by Country (2021-2026) & (US$ Million)
Table 32. North America Retinal Degenerative Disease Treatment Market Size by Country (2027-2032) & (US$ Million)
Table 33. Europe Retinal Degenerative Disease Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 34. Europe Retinal Degenerative Disease Treatment Market Size by Country (2021-2026) & (US$ Million)
Table 35. Europe Retinal Degenerative Disease Treatment Market Size by Country (2027-2032) & (US$ Million)
Table 36. Asia Pacific Retinal Degenerative Disease Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 37. Asia Pacific Retinal Degenerative Disease Treatment Market Size by Region (2021-2026) & (US$ Million)
Table 38. Asia Pacific Retinal Degenerative Disease Treatment Market Size by Country (2027-2032) & (US$ Million)
Table 39. South America Retinal Degenerative Disease Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 40. South America Retinal Degenerative Disease Treatment Market Size by Country (2021-2026) & (US$ Million)
Table 41. South America Retinal Degenerative Disease Treatment Market Size by Country (2027-2032) & (US$ Million)
Table 42. Middle East & Africa Retinal Degenerative Disease Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 43. Middle East & Africa Retinal Degenerative Disease Treatment Market Size by Country (2021-2026) & (US$ Million)
Table 44. Middle East & Africa Retinal Degenerative Disease Treatment Market Size by Country (2027-2032) & (US$ Million)
Table 45. Sucampo Pharmaceuticals Company Information
Table 46. Sucampo Pharmaceuticals Business Overview
Table 47. Sucampo Pharmaceuticals Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million)
Table 48. Sucampo Pharmaceuticals Retinal Degenerative Disease Treatment Product Portfolio
Table 49. Sucampo Pharmaceuticals Recent Developments
Table 50. Vivani Medical(Second Sight Medical) Company Information
Table 51. Vivani Medical(Second Sight Medical) Business Overview
Table 52. Vivani Medical(Second Sight Medical) Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million)
Table 53. Vivani Medical(Second Sight Medical) Retinal Degenerative Disease Treatment Product Portfolio
Table 54. Vivani Medical(Second Sight Medical) Recent Developments
Table 55. Roche Company Information
Table 56. Roche Business Overview
Table 57. Roche Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million)
Table 58. Roche Retinal Degenerative Disease Treatment Product Portfolio
Table 59. Roche Recent Developments
Table 60. ReNeuron Company Information
Table 61. ReNeuron Business Overview
Table 62. ReNeuron Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million)
Table 63. ReNeuron Retinal Degenerative Disease Treatment Product Portfolio
Table 64. ReNeuron Recent Developments
Table 65. ReGenX Biosciences Company Information
Table 66. ReGenX Biosciences Business Overview
Table 67. ReGenX Biosciences Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million)
Table 68. ReGenX Biosciences Retinal Degenerative Disease Treatment Product Portfolio
Table 69. ReGenX Biosciences Recent Developments
Table 70. Regeneron Pharmaceuticals Company Information
Table 71. Regeneron Pharmaceuticals Business Overview
Table 72. Regeneron Pharmaceuticals Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million)
Table 73. Regeneron Pharmaceuticals Retinal Degenerative Disease Treatment Product Portfolio
Table 74. Regeneron Pharmaceuticals Recent Developments
Table 75. Orphagen Pharmaceuticals, Inc. Company Information
Table 76. Orphagen Pharmaceuticals, Inc. Business Overview
Table 77. Orphagen Pharmaceuticals, Inc. Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million)
Table 78. Orphagen Pharmaceuticals, Inc. Retinal Degenerative Disease Treatment Product Portfolio
Table 79. Orphagen Pharmaceuticals, Inc. Recent Developments
Table 80. Okuvision Company Information
Table 81. Okuvision Business Overview
Table 82. Okuvision Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million)
Table 83. Okuvision Retinal Degenerative Disease Treatment Product Portfolio
Table 84. Okuvision Recent Developments
Table 85. Ocugen Company Information
Table 86. Ocugen Business Overview
Table 87. Ocugen Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million)
Table 88. Ocugen Retinal Degenerative Disease Treatment Product Portfolio
Table 89. Ocugen Recent Developments
Table 90. Novartis Company Information
Table 91. Novartis Business Overview
Table 92. Novartis Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million)
Table 93. Novartis Retinal Degenerative Disease Treatment Product Portfolio
Table 94. Novartis Recent Developments
Table 95. Nano Retina Company Information
Table 96. Nano Retina Business Overview
Table 97. Nano Retina Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million)
Table 98. Nano Retina Retinal Degenerative Disease Treatment Product Portfolio
Table 99. Nano Retina Recent Developments
Table 100. M's Science Corporation Company Information
Table 101. M's Science Corporation Business Overview
Table 102. M's Science Corporation Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million)
Table 103. M's Science Corporation Retinal Degenerative Disease Treatment Product Portfolio
Table 104. M's Science Corporation Recent Developments
Table 105. Mimetogen Pharmaceuticals Inc. Company Information
Table 106. Mimetogen Pharmaceuticals Inc. Business Overview
Table 107. Mimetogen Pharmaceuticals Inc. Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million)
Table 108. Mimetogen Pharmaceuticals Inc. Retinal Degenerative Disease Treatment Product Portfolio
Table 109. Mimetogen Pharmaceuticals Inc. Recent Developments
Table 110. Kanghong Pharma Company Information
Table 111. Kanghong Pharma Business Overview
Table 112. Kanghong Pharma Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million)
Table 113. Kanghong Pharma Retinal Degenerative Disease Treatment Product Portfolio
Table 114. Kanghong Pharma Recent Developments
Table 115. Ionis Pharmaceuticals, Inc. Company Information
Table 116. Ionis Pharmaceuticals, Inc. Business Overview
Table 117. Ionis Pharmaceuticals, Inc. Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million)
Table 118. Ionis Pharmaceuticals, Inc. Retinal Degenerative Disease Treatment Product Portfolio
Table 119. Ionis Pharmaceuticals, Inc. Recent Developments
Table 120. International Stem Cell Corporation Company Information
Table 121. International Stem Cell Corporation Business Overview
Table 122. International Stem Cell Corporation Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million)
Table 123. International Stem Cell Corporation Retinal Degenerative Disease Treatment Product Portfolio
Table 124. International Stem Cell Corporation Recent Developments
Table 125. InFlectis BioScience Company Information
Table 126. InFlectis BioScience Business Overview
Table 127. InFlectis BioScience Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million)
Table 128. InFlectis BioScience Retinal Degenerative Disease Treatment Product Portfolio
Table 129. InFlectis BioScience Recent Developments
Table 130. Grupo Ferrer Internacional, S.A. Company Information
Table 131. Grupo Ferrer Internacional, S.A. Business Overview
Table 132. Grupo Ferrer Internacional, S.A. Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million)
Table 133. Grupo Ferrer Internacional, S.A. Retinal Degenerative Disease Treatment Product Portfolio
Table 134. Grupo Ferrer Internacional, S.A. Recent Developments
Table 135. GenSight Biologics S.A. Company Information
Table 136. GenSight Biologics S.A. Business Overview
Table 137. GenSight Biologics S.A. Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million)
Table 138. GenSight Biologics S.A. Retinal Degenerative Disease Treatment Product Portfolio
Table 139. GenSight Biologics S.A. Recent Developments
Table 140. Genethon Company Information
Table 141. Genethon Business Overview
Table 142. Genethon Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million)
Table 143. Genethon Retinal Degenerative Disease Treatment Product Portfolio
Table 144. Genethon Recent Developments
Table 145. Genable Technologies Limited Company Information
Table 146. Genable Technologies Limited Business Overview
Table 147. Genable Technologies Limited Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million)
Table 148. Genable Technologies Limited Retinal Degenerative Disease Treatment Product Portfolio
Table 149. Genable Technologies Limited Recent Developments
Table 150. Dompe Farmaceutici S.p.A. Company Information
Table 151. Dompe Farmaceutici S.p.A. Business Overview
Table 152. Dompe Farmaceutici S.p.A. Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million)
Table 153. Dompe Farmaceutici S.p.A. Retinal Degenerative Disease Treatment Product Portfolio
Table 154. Dompe Farmaceutici S.p.A. Recent Developments
Table 155. Caladrius Biosciences, Inc. Company Information
Table 156. Caladrius Biosciences, Inc. Business Overview
Table 157. Caladrius Biosciences, Inc. Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million)
Table 158. Caladrius Biosciences, Inc. Retinal Degenerative Disease Treatment Product Portfolio
Table 159. Caladrius Biosciences, Inc. Recent Developments
Table 160. Bayer HealthCare Company Information
Table 161. Bayer HealthCare Business Overview
Table 162. Bayer HealthCare Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million)
Table 163. Bayer HealthCare Retinal Degenerative Disease Treatment Product Portfolio
Table 164. Bayer HealthCare Recent Developments
Table 165. Astellas Pharma Inc. Company Information
Table 166. Astellas Pharma Inc. Business Overview
Table 167. Astellas Pharma Inc. Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million)
Table 168. Astellas Pharma Inc. Retinal Degenerative Disease Treatment Product Portfolio
Table 169. Astellas Pharma Inc. Recent Developments
Table 170. Amarantus BioScience Company Information
Table 171. Amarantus BioScience Business Overview
Table 172. Amarantus BioScience Revenue in Retinal Degenerative Disease Treatment Business (2021-2026) & (US$ Million)
Table 173. Amarantus BioScience Retinal Degenerative Disease Treatment Product Portfolio
Table 174. Amarantus BioScience Recent Developments
Table 175. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Retinal Degenerative Disease Treatment Product Image
Figure 5. Global Retinal Degenerative Disease Treatment Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 6. Global Retinal Degenerative Disease Treatment Market Share by Type: 2025 VS 2032
Figure 7. Age Related Macular Degeneration (AMD) Treatment Product
Figure 8. Retinitis Pigmentosa (RP) Treatment Product
Figure 9. Global Retinal Degenerative Disease Treatment Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 10. Global Retinal Degenerative Disease Treatment Market Share by Application: 2025 VS 2032
Figure 11. 20 to 60 Years Old Product
Figure 12. 60 and Over Product
Figure 13. Others Product
Figure 14. Global Retinal Degenerative Disease Treatment Market Size (US$ Million), Year-over-Year: 2021-2032
Figure 15. Global Retinal Degenerative Disease Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032
Figure 16. Global Retinal Degenerative Disease Treatment Market Share by Region: 2025 VS 2032
Figure 17. Global Retinal Degenerative Disease Treatment Market Share by Players in 2025
Figure 18. Global Retinal Degenerative Disease Treatment Manufacturers Established Date
Figure 19. Global Top 5 and 10 Retinal Degenerative Disease Treatment Players Market Share by Revenue in 2025
Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 21. North America Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 22. North America Retinal Degenerative Disease Treatment Market Share by Country (2021-2032)
Figure 23. United States Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 24. Canada Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 25. Mexico Retinal Degenerative Disease Treatment Market Share by Country (2021-2032)
Figure 26. Europe Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 27. Europe Retinal Degenerative Disease Treatment Market Share by Country (2021-2032)
Figure 28. Germany Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 29. France Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 30. U.K. Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 31. Italy Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 32. Spain Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 33. Russia Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 34. Netherlands Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 35. Nordic Countries Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 36. Asia-Pacific Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 37. Asia-Pacific Retinal Degenerative Disease Treatment Market Share by Country (2021-2032)
Figure 38. China Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 39. Japan Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 40. South Korea Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 41. India Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 42. India Retinal Degenerative Disease Treatment Market Share by Country (2021-2032)
Figure 43. Australia Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 44. China Taiwan Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 45. Southeast Asia Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 46. South America Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 47. South America Retinal Degenerative Disease Treatment Market Share by Country (2021-2032)
Figure 48. Brazil Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 49. Argentina Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 50. Chile Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 51. Colombia Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 52. Peru Retinal Degenerative Disease Treatment Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 53. Sucampo Pharmaceuticals Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026)
Figure 54. Vivani Medical(Second Sight Medical) Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026)
Figure 55. Roche Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026)
Figure 56. ReNeuron Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026)
Figure 57. ReGenX Biosciences Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026)
Figure 58. Regeneron Pharmaceuticals Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026)
Figure 59. Orphagen Pharmaceuticals, Inc. Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026)
Figure 60. Okuvision Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026)
Figure 61. Ocugen Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026)
Figure 62. Novartis Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026)
Figure 63. Nano Retina Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026)
Figure 64. M's Science Corporation Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026)
Figure 65. Mimetogen Pharmaceuticals Inc. Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026)
Figure 66. Kanghong Pharma Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026)
Figure 67. Ionis Pharmaceuticals, Inc. Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026)
Figure 68. International Stem Cell Corporation Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026)
Figure 69. InFlectis BioScience Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026)
Figure 70. Grupo Ferrer Internacional, S.A. Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026)
Figure 71. GenSight Biologics S.A. Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026)
Figure 72. Genethon Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026)
Figure 73. Genable Technologies Limited Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026)
Figure 74. Dompe Farmaceutici S.p.A. Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026)
Figure 75. Caladrius Biosciences, Inc. Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026)
Figure 76. Bayer HealthCare Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026)
Figure 77. Astellas Pharma Inc. Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026)
Figure 78. Amarantus BioScience Revenue Growth Rate in Retinal Degenerative Disease Treatment Business (2021-2026)
提及公司
Sucampo PharmaceuticalsVivani Medical(Second Sight Medical)RocheReNeuronReGenX BiosciencesRegeneron PharmaceuticalsOrphagen Pharmaceuticals, Inc.OkuvisionOcugenNovartisNano RetinaM's Science CorporationMimetogen Pharmaceuticals Inc.Kanghong PharmaIonis Pharmaceuticals, Inc.International Stem Cell CorporationInFlectis BioScienceGrupo Ferrer Internacional, S.A.GenSight Biologics S.A.GenethonGenable Technologies LimitedDompe Farmaceutici S.p.A.Caladrius Biosciences, Inc.Bayer HealthCareAstellas Pharma Inc.Amarantus BioScience
量子訊息有限公司為 APO Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們